[Skip to Content]
Visit our RSS Feed View our RSS Feed
PHDL Me This June 19th, 2024
CategoriesCategoriesCategories Contact UsContact Us ArchivesArchives Region/OfficeOur Office SearchSearch



Date prong graphic

COVID-19 Vaccine Candidate Begins Phase 3 Clinical Trial

Posted by on September 1st, 2020 Posted in: Blog

Scientists at Rocky Mountain Laboratories in Hamilton, Montana,conducted a preclinical study of the investigational vaccine AZD1222, their findings were recently published in Nature.  AZD122 uses a viral vector to deliver a SARS-CoV-2 spike protein to induce immune response.

See the full news release at Phase 3 Clinical Testing in the US of AstraZeneca COVID-19 Vaccine Candidate Begins (August 31, 2020)

The NIAID COVID-19 Prevention Network (CoVPN) will participate in the Phase 3 clinical trial of AZD1222 in the United States. The CoVPN is composed of existing NIAID-supported clinical research networks with infectious disease expertise and is designed for evaluation of vaccine candidates and antibodies for the prevention of COVID-19.

The Phase 3 trial is being implemented as part of Operation Warp Speed, a multi-agency collaboration led by HHS accelerating the development, manufacturing and distribution of medical countermeasures for COVID-19.

“NIH is committed to supporting several Phase 3 vaccine trials to increase the odds that one or more will be effective in preventing COVID-19 and put us on the road to recovery from this devastating pandemic,” said NIH Director Francis S. Collins, M.D., Ph.D.

The trial will enroll approximately 30,000 adult volunteers at 80 sites in the United States.

Image of the author ABOUT Javier Crespo

Email author View all posts by

Subscribe to Newsletter

Search Content

NNLM Public Health Coordination Office University of Massachusetts Medical School 55 Lake Avenue North Worcester, MA 01655 (508) 856-7633
This has been funded in whole or in part with Federal funds from the Department of Health and Human Services, National Institutes of Health, National Library of Medicine, under cooperative agreement number UG4LM012347 with the University of Massachusetts Medical School.

NNLM and NETWORK OF THE NATIONAL LIBRARY OF MEDICINE are service marks of the US Department of Health and Human Services | Copyright | HHS Vulnerability Disclosure | Download PDF Reader